can i switch to semaglutide from tirzepatide Switching for Weight Loss should i switch from tirzepatide

Targeting metabolism in aortic aneurysm and dissection: from basic research to clinical applications

GLP-1-based therapies have been a pillar in the treatment landscape for T2D and more recently for obesity

Next-generation agents, including triple agonists such as retatrutide, extend beyond GLP-1 and GIP to include glucagon receptor activation, introducing a new dimension of energy expenditure and metabolic regulation

Kastin et al., 2002

There is no protocol justification for combining the two outside direct clinician supervision

This means KLOW targets the root cause of the chronic inflammation driving many conditions, rather than merely masking symptoms